Pembrolizumab (Keytruda®) adjuvant treatment of stage IIB or IIC melanoma. HTA ID: 22042

Assessment Status NCPE Assessment Process Complete
HTA ID 22042
Drug Pembrolizumab
Brand Keytruda®
Indication Is indicated for the adjuvant treatment of adults and adolescent (≥12 years) with stage IIB or IIC melanoma following complete resection.
Assessment Process
Rapid review commissioned 22/06/2022
Rapid review completed 14/07/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 27/07/2022
Pre-submission consultation with Applicant 15/11/2022
Full submission received from Applicant 27/07/2023
Preliminary review sent to Applicant 21/12/2023
NCPE assessment re-commenced 01/02/2024
Factual accuracy sent to Applicant 28/03/2024
NCPE assessment re-commenced 05/04/2024
NCPE assessment completed 14/05/2024
NCPE assessment outcome The NCPE recommends that pembrolizumab be considered for reimbursement, for this indication, if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.